ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded a delivery order to TEVA PHARMACEUTICALS USA, INC. under the base contract SPE2DP20D0002 for the supply of 18.000 packages of Adenovirus Type 4 and Type 7 Live Vaccine, identified by NSN 6505016420106 and NDC 51285-0138-50, at a total contract price of $343,526.40. The award was issued on July 14, 2026, with delivery required to be completed by July 21, 2026, under FOB Destination terms where the contractor assumes all freight costs and responsibility for safe transport. The vaccine must be shipped using traceable methods—parcel post is prohibited—and all packaging must be properly marked with identification numbers from Blocks 1 and 2 of the order, including mandatory MARKFOR identifiers such as W25MWY61940720, to ensure government logistics tracking. The contractor is designated as a small business and is responsible for conforming to all specifications and packaging requirements aligned with DoD procurement protocols, though specific MIL-STD references are not explicitly cited. Delivery is primarily directed to Fort Sill, Oklahoma, with a secondary ship-to location at Fort Detrick, Maryland. Payment will be processed electronically via WAWF in accordance with DFARS 252.232-7003, with remittance handled by DEF FIN AND ACCOUNTING SVC in Columbus, Ohio, and no separate COR or COTR is designated, leaving the contracting officer, Melissa Rios Thomas, as the primary point of contact for administrative and contractual matters. The order is a firm-fixed-price, no-option award under an IDIQ vehicle, with full technical and quality compliance verified by the government upon receipt at the destination, and adherence to small business certification obligations triggers reporting requirements through SAM.gov.